Skip to search boxSkip to navigationSkip to main content

C9orf72 Hexanucleotide Repeat in Huntington-Like Patients: Systematic Review and Meta-Analysis

  • ,
  • Christoper A. Alarcon-Ruiz
    ,
  • Kevin Pacheco-Barrios
    ,
  • Nicanor Mori
    ,
  • Josmel Pacheco-Mendoza
    ,
  • Bryan J. Traynor
  • ,
  • Universidad Científica del Sur
    ,
  • Universidad San Ignacio de Loyola
    ,
  • Hospital Daniel Alcides Carrión
    ,
  • NIH
    ,
  • Fogarty Interdisciplinary Cerebrovascular Diseases Training Program in South America
Research Output: Contribution to journal Review article Peer-review

Open access

Publication Information

Output type

Research Output: Contribution to journal Review article Peer-review

Original language

English

Article number

551780

Journal (Volume, Issue Number)

Frontiers in Genetics (Volume 11)

Publication milestones

  • Published - 02/11/2020

Publication status

Published - 02/11/2020

Publication IDs

  • Scopus: 85096170056

Abstract

Introduction: Patients with Huntington-Like disorders (HLD) comprise a variety of allelic disorders sharing a Huntington phenotype. The hexanucleotide repeat expansion of the C9orf72 gene could explain part of the HLD etiology. We aimed to conduct a systematic review and meta-analysis looking for the frequency of the hexanucleotide repeat expansion of the C9orf72 gene in HLD patients. Methods: The protocol was registered on the International Prospective Register of Systematic Reviews database (PROSPERO) (registration number: CRD42018105465). The search was carried out in Medline, Scopus, Web of Science, and Embase in April 2018, and updated in July 2020. Observational studies reporting patients with HLD carrying the hexanucleotide repeat expansion in the C9orf72 gene were selected and reviewed; this process was duplicated. The cutoff threshold for considering the hexanucleotide expansion as a pathogenic variant was equal to or >30 G4C2 repeats. Cases with intermediate alleles with 20–29 repeat are also analyzed. Pooled frequency and 95% CI were calculated using random-effects models. Results: Nine out of 219 studies were selected, reporting 1,123 affected individuals with HLD. Among them, 18 individuals carried C9orf72 expansion, representing 1% (95% CI: 0–2%, I2 = 0%) of the pooled frequency. Seven selected studies came from European centers, one was reported at a US center, and one came from a South-African center. We identified five individuals carrying intermediate alleles representing 3% (95% CI: 0–14%, I2 = 78.5%). Conclusions: The frequency of C9orf72 unstable hexanucleotide repeat expansion in HLD patients is very low. Further studies with more accurate clinical data and from different ethnic backgrounds are needed to confirm this observation.

Funding Details

This work was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (Z01-AG000949-02). Research reported in this publication was partially supported by the Fogarty International Center (FIC) of the NIH and NINDS (D43TW009345 and D43TW009137).
FundersFunding numbers
NIH
-
NIA
Z01-AG000949-02
FIC
-
NINDS
D43TW009345, D43TW009137

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Mentions
1
Social media
58
Captures
18
Citations
6